site stats

Kangpu biopharmaceuticals

Webb27 feb. 2024 · Patent number: 10017492. Abstract: Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and … Webb17 nov. 2024 · Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders through novel-generation solutions including targeted protein ubiquitination …

Abstract 6367: KPG-818, a novel cereblon modulator, inhibits ...

WebbKangpu Biopharmaceuticals, Ltd. and Alpha Biopharma share similar industries and funding stages . Save These companies are similar. Hangzhou Just Biotherapeutics (Just China) Hangzhou, Zhejiang, China 51-100 employees . … Webb15 aug. 2024 · The clinical use of lenalidomide in multiple myeloma (MM), mantle cell lymphoma (MCL) and myelodysplastic syndromes (MDS) represents a significant advance in the treatment of hematological malignancies and has altered the landscape of the blood cancer therapy. cmoney 00878 https://manteniservipulimentos.com

Kangpu Biopharmaceuticals - Overview, News & Competitors

WebbReferrals increase your chances of interviewing at Kangpu Biopharmaceuticals, Ltd. by 2x See who you know Get notified about new Budget Specialist jobs in New Jersey, United States . WebbOriginator Kangpu Biopharmaceuticals Developer Accelovance; Kangpu Biopharmaceuticals Class Antineoplastics; Small molecules Mechanism of Action … WebbKangpu Biopharmaceuticals (Kangpu) focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological … cmoney 1560

Kangpu Biopharmaceuticals - Overview, News & Competitors

Category:Yong GUO - SVP Clinical Development - Kangpu Biopharmaceuticals…

Tags:Kangpu biopharmaceuticals

Kangpu biopharmaceuticals

预见未来 中国蛋白降解药物研发进展如何？这些疗法有何特点？

Webb20 mars 2024 · Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid … WebbYANJUN DENG, MS, JM. SVP, Legal & Risk Management, Kangpu Biopharmaceuticals, Ltd. CHUANSHENG GE, PhD. Co-Founder, Chairman & CEO, Kangpu …

Kangpu biopharmaceuticals

Did you know?

Webb11 okt. 2024 · SHANGHAI, China I October 11, 2024 I Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted in the United States.. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and … WebbSpeaker Testimonials. Benika Pinch. Novartis. "This meeting is an exciting opportunity to learn about new approaches and opportunities within targeted protein degradation, which will accelerate the development of future therapeutics!" David Wang. Kangpu Biopharmaceuticals. "As one of the leading global forums in targeted protein …

Webb16 mars 2024 · At a glance Originator Kangpu Biopharmaceuticals Class Anti-inflammatories; Antineoplastics; Small molecules Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase complex modulators Orphan Drug Status No New Molecular Entity Yes Highest Development Phases Phase I/II Systemic lupus … Webb17 nov. 2024 · Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders through novel-generation solutions including targeted protein ubiquitination …

Webb5 feb. 2024 · "Kangpu Biopharmaceuticals, Ltd. is spearheading this trial and require a total of 60 qualified participants to conduct the study. It will be conducted in different locations such as Shelby Research LLC in Memphis, Tennessee and Altoona Center for Clinical Research in Duncansville, Pennsylvania." - Anonymous Online Contributor Webb13 juni 2024 · SHANGHAI, June 12, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDES TM molecular glue, for the treatment of systemic lupus …

Webb9 maj 2024 · 研发公司：康朴生物（Kangpu Biopharmaceuticals） 疾病：系统性红斑狼疮、COVID-19（KPG-818）；转移性和非转移性去势抵抗性前列腺癌（KPG-121） 康朴生物目前共有5条蛋白降解药物管线，其中2款药物KPG-818和KPG-121已经进入临床试验阶段，3款药物KPG-419、KP-0936S和KP-0696S处于临床前阶段。

WebbKangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, … cmoney 2104Webb18 aug. 2024 · Kangpu Biopharmaceuticals, Ltd. Investigators None specified. Study Documents (Full-Text) None provided. More Information Publications None provided. Responsible Party: Kangpu Biopharmaceuticals, Ltd. ClinicalTrials.gov Identifier: NCT04643067. Other Study ID Numbers: KPG-818-SLE; cafe merlingueWebb中国上海，2024年3月13日 -- 康朴生物医药技术（上海）有限公司（“康朴生物医药”），一家处于临床阶段、致力于通过分子胶蛋白质降解等技术开发用于治疗癌症、自身免疫疾 … cmoney 2221